PMS-IRBESARTAN-HCTZ TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

IRBESARTAN; HYDROCHLOROTHIAZIDE

Pieejams no:

PHARMASCIENCE INC

ATĶ kods:

C09DA04

SNN (starptautisko nepatentēto nosaukumu):

IRBESARTAN AND DIURETICS

Deva:

300MG; 12.5MG

Zāļu forma:

TABLET

Kompozīcija:

IRBESARTAN 300MG; HYDROCHLOROTHIAZIDE 12.5MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

Prescription

Ārstniecības joma:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0240086002; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2011-03-21

Produkta apraksts

_pms-IRBESARTAN-HCTZ (irbesartan and hydrochlorothiazide) _
_Page 1 of 54_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-IRBESARTAN-HCTZ
Irbesartan and Hydrochlorothiazide Tablets
Tablets, 150 mg/12.5 mg, 300 mg/12.5 mg and 300 mg/25 mg, Oral
House Standard
Angiotensin II AT
1
Receptor Blocker / Diuretic
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
www.pharmascience.com
Date of Initial Authorization:
MAR 21, 2011
Date of Revision:
APR 12, 2023
Submission Control Number: 273098
_pms-IRBESARTAN-HCTZ (irbesartan and hydrochlorothiazide) _
_Page 2 of 54_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism
06/2021
7 WARNINGS AND PRECAUTIONS, Ophthalmologic
06/2021
7 Warnings and Precautions, Respiratory
04/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
.................................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................. 5
4
DOSAGE AND ADMINISTRATION
..................................................................................
5
4.1
Dosing Considerations
..................